Convalescent Plasma Therapy in Severe COVID-19 Patients: Retrospective Study

Background: Covid-19 is infectious disease that caused by SARS-COV2 Virus. There is no definitive treatment for Covid-19 until now. Convalescent plasma therapy is one of therapy that considered to provide good outcome for Covid-19 patient.In developing country, convalescent plasma is difficult to obtain because there are requirements for donors. There is a time gap between patient?s admission day and first day convalescent plasma administered to patient. The purpose of this article is to explore the association betweentiming of convalescent plasma therapy with outcome in severe covid-19 patient. Method: This study is retrospective study using secondary data of patient?s medical record at Wangaya Hospital, Denpasar, between September 2020 and March 2021. Inclusion criteria is set in this study, include severe Covid-19 patient that had administered convalescent plasma therapy. Result: 32 sample was obtained in this study. Data was analyzed with Kolmogorov smirnov normality test, results is not normally distributed (p=0.003). Fisher exact analysis was performed. We found that there is no significant difference in outcome in severe Covid-19 patient that was given convalescent plasma before and after 3 days admission to hospital (p=1.000, CI 95%). We also found that there is no significant difference in outcome in severe Covid-19 patient that was given convalescent plasma before and after 5 days admission to hospital (p=1.000, CI 95%). Conclusion: There is no significant difference between timing of convalescent plasma therapy and outcome in severe Covid-19 patient. However, further research are needed to explain the effect of convalescent plasma therapy in severe Covid-19 patient.